



February 5, 2013

BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- [BioCryst Pharmaceuticals, Inc.](#) (NASDAQ:BCRX) today announced that its fourth quarter and full year 2012 financial results will be released on Tuesday, February 19, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by [Jon P. Stonehouse](#), President and Chief Executive Officer, [Thomas R. Staab, II](#), Senior Vice President and Chief Financial Officer and [Dr. William P. Sheridan](#), Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst currently has two late-stage development programs: [peramivir](#), a viral neuraminidase inhibitor for the treatment of influenza, and [ulodesine](#), a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst has several early-stage programs: [BCX4161](#) and a next generation oral inhibitor of plasma kallikrein for hereditary angioedema and [BCX4430](#), a broad spectrum antiviral for hemorrhagic fevers. For more information, please visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910

Source: BioCryst Pharmaceuticals, Inc.

News Provided by Acquire Media